Immunotherapy

ASCO: Teclistamab Improves Survival in Relapsed, Refractory Multiple Myeloma

Physician’s Briefing

ASCO: Teclistamab Improves Survival in Relapsed, Refractory Multiple Myeloma

3 hours ago

2 min read

ASCO: Intismeran Plus Pembrolizumab Ups RFS, DMFS in High-Risk Melanoma

Physician’s Briefing

ASCO: Intismeran Plus Pembrolizumab Ups RFS, DMFS in High-Risk Melanoma

01 Jun 2026

2 min read

Peanut OIT Safe With Slow Up-Dosing, Low Maintenance Dosing

Physician’s Briefing

Peanut OIT Safe With Slow Up-Dosing, Low Maintenance Dosing

14 May 2026

2 min read

Read More

Clinical Briefing Report

clinicalbriefingreport.com